LFCR - Rasio utang marang kapitalisasi buku lifecore.com

Logo grafis Lifecore Biomedical, Inc. (LFCR)

Lifecore Biomedical (LFCR) business relies on steady domestic demand for medical developments, rendering it a defensive asset, although the company is heavily dependent on external raw material suppliers. This chart from GURU.Markets with a value of 9.05 visualizes the asset's price action. Experienced management specializing in the production of complex biologics and high-quality hyaluronic acid at full plant capacity ensures the firm's success.

LFCR (Lifecore Biomedical, Inc.) riwayat Utang marang nilai buku saka 28.04.2023 nganti 27.10.2026

Ringkesan rincian data analitis lifecore.com (LFCR)

- rega lan prakiraan konsensus rega:
Rega saham Lifecore Biomedical, Inc.|LFCR - Prakiraan konsensus analis
- data kapitalisasi pasar:
Nilai pasar Lifecore Biomedical, Inc.|LFCR - Nilai Dipunlarasaken Utang lan Kas
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Lifecore Biomedical|LFCR - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku lifecore.com|LFCR - Total Aset Perusahaan
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas Lifecore Biomedical|LFCR - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Lifecore Biomedical, Inc.|LFCR - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Lifecore Biomedical, Inc.
Analisis fundamental perusahaan:Lifecore - LFCR
Barang utama Lifecore Biomedical Inc.

Professional managers utilize fundamental filters to assess capital structure stability, where the debt-to-asset ratio determines the degree of financial risk. For Lifecore Biomedical (LFCR), whose certified injection manufacturing capacities generate a stable cash flow, the level of debt concentration within the balance sheet capitalization confirms the company's ability to service its obligations without compromising operational efficiency.

Karo sapa Lifecore Biomedical saingan

Utang-utang marang kapitalisasi buku IQV (IQVIA Holdings Inc.)|labcorp.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Medpace (MEDP)|ICLR: Rasio utang marang aset resik|CRL (Charles River Lab) - Rasio utang marang kapitalisasi buku|Evotec Group (EVO) - Utang marang nilai buku|FTRE (Fortrea Holdings Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku omniab.com (OABI)|Inotiv (NOTV) - Utang marang nilai buku|Rasio utang marang aset resik Avid Bioservices Inc. CDMO|Utang marang nilai buku Catalent Pharma Solutions (CTLT)|Utang marang modal buku Scorpius Holdings, Inc SCPX